Clinical Trial Update: Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update assessing efficacy and safety of JMT101 plus osimertinib in non-small cell lung cancer with EGFR Exon 20 insertion mutations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• JMT101
• Osimertinib (osimertinib)

Snippet

Sponsor: Shanghai JMT-Bio Inc. | Conditions: Locally Advanced or Metastatic Non-Small Cell Lung Cancer, EGFR Exon20 Insertion Mutations | Phase 2 | Status: UNKNOWN